[go: up one dir, main page]

CY1115251T1 - Θεραπεια λευχαιμιας ανθεκτικης σε ιματινιμπη χρησιμοποιωντας 4-αμινοκινολινο-3-καρβονιτριλια - Google Patents

Θεραπεια λευχαιμιας ανθεκτικης σε ιματινιμπη χρησιμοποιωντας 4-αμινοκινολινο-3-καρβονιτριλια

Info

Publication number
CY1115251T1
CY1115251T1 CY20141100395T CY141100395T CY1115251T1 CY 1115251 T1 CY1115251 T1 CY 1115251T1 CY 20141100395 T CY20141100395 T CY 20141100395T CY 141100395 T CY141100395 T CY 141100395T CY 1115251 T1 CY1115251 T1 CY 1115251T1
Authority
CY
Cyprus
Prior art keywords
carbonitrile
aminokinolino
therapy treatment
imatinib
leukemia therapy
Prior art date
Application number
CY20141100395T
Other languages
English (en)
Inventor
Becker Hewes
Original Assignee
Wyeth Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39639071&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1115251(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Llc filed Critical Wyeth Llc
Publication of CY1115251T1 publication Critical patent/CY1115251T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Η παρούσα εφεύρεση παρέχει ενώσεις 4-αμινοκινολινο-3-καρβονιτριλίου χρήσιμες για θεραπεία ενός υποκειμένου που έχει θετική σε BcrAbl λευχαιμία που είναι ανθεκτική σε ιματινίμπη.
CY20141100395T 2007-06-01 2014-06-03 Θεραπεια λευχαιμιας ανθεκτικης σε ιματινιμπη χρησιμοποιωντας 4-αμινοκινολινο-3-καρβονιτριλια CY1115251T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US93265007P 2007-06-01 2007-06-01
EP12160638.8A EP2478905B1 (en) 2007-06-01 2008-05-30 Treatment of imatinib resistant leukemia using 4-aminoquinoline-3-carbonitriles

Publications (1)

Publication Number Publication Date
CY1115251T1 true CY1115251T1 (el) 2017-01-04

Family

ID=39639071

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20141100395T CY1115251T1 (el) 2007-06-01 2014-06-03 Θεραπεια λευχαιμιας ανθεκτικης σε ιματινιμπη χρησιμοποιωντας 4-αμινοκινολινο-3-καρβονιτριλια
CY20211100693T CY1124391T1 (el) 2007-06-01 2021-08-03 Θεραπεια ανθεκτικης σε ιματινιμπη χρονιας μυελογενους λευχαιμιας που εχει τη μεταλλαξη 1457t>c στο bcrabl γονιδιο χρησιμοποιωντας την ενωση μποσουτινιμπη

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY20211100693T CY1124391T1 (el) 2007-06-01 2021-08-03 Θεραπεια ανθεκτικης σε ιματινιμπη χρονιας μυελογενους λευχαιμιας που εχει τη μεταλλαξη 1457t>c στο bcrabl γονιδιο χρησιμοποιωντας την ενωση μποσουτινιμπη

Country Status (23)

Country Link
US (1) US11103497B2 (el)
EP (4) EP2777704A3 (el)
JP (3) JP5888853B2 (el)
KR (1) KR101493543B1 (el)
CN (1) CN101686973B (el)
AU (1) AU2008260070B9 (el)
BR (1) BRPI0812355A2 (el)
CA (3) CA2868899C (el)
CL (1) CL2008001577A1 (el)
CY (2) CY1115251T1 (el)
DK (2) DK2478905T3 (el)
ES (2) ES2881391T3 (el)
HU (1) HUE055524T2 (el)
IL (1) IL202407A0 (el)
MX (1) MX2009013069A (el)
PA (1) PA8782301A1 (el)
PL (2) PL2478905T3 (el)
PT (2) PT3002009T (el)
RU (1) RU2464026C2 (el)
SI (2) SI2478905T1 (el)
TW (1) TW200908982A (el)
WO (1) WO2008150957A2 (el)
ZA (1) ZA200908480B (el)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2868899C (en) * 2007-06-01 2017-06-13 Wyeth Llc Treatment of imatinib resistant leukemia using 4-aminoquinoline-3-carbonitriles having mutation in the bcrabl gene
ES2609578T3 (es) 2011-03-04 2017-04-21 Glaxosmithkline Intellectual Property Development Limited Amino-quinolinas como inhibidores de quinasa
TWI547494B (zh) 2011-08-18 2016-09-01 葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之胺基喹唑啉類
TW201425307A (zh) 2012-09-13 2014-07-01 Glaxosmithkline Llc 作為激酶抑制劑之胺基－喹啉類
TWI592417B (zh) 2012-09-13 2017-07-21 葛蘭素史克智慧財產發展有限公司 胺基喹唑啉激酶抑制劑之前藥
BR112015019624A2 (pt) 2013-02-21 2017-07-18 Glaxosmithkline Ip Dev Ltd quinazolinas como inibidores de quinase
KR101733665B1 (ko) * 2015-05-06 2017-05-10 재단법인 지능형 바이오 시스템 설계 및 합성 연구단 진세노사이드 Ｆ1 또는 Ｒｇ3을 유효성분으로 포함하는 글리벡 내성 백혈병 예방 또는 치료용 약학 조성물
US20220388962A1 (en) * 2019-08-22 2022-12-08 Biohaven Therapeutics Ltd. Molecules that bind to tdp-43 for the treatment of amyotrophic lateral sclerosis and related disorders
CN115944636A (zh) * 2022-11-01 2023-04-11 华南师范大学 博舒替尼在抑制i-motif结构上的应用
WO2025024311A2 (en) * 2023-07-21 2025-01-30 Icahn School Of Medicine At Mount Sinai G9a/glp inhibitors and methods of use

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6002008A (en) 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
US6297258B1 (en) 1998-09-29 2001-10-02 American Cyanamid Company Substituted 3-cyanoquinolines
WO2002058700A1 (en) * 2001-01-25 2002-08-01 Bristol-Myers Squibb Company Methods of administering epothilone analogs for the treatment of cancer
WO2003031608A2 (en) 2001-10-05 2003-04-17 Novartis Ag Mutated abl kinase domains
TWI275390B (en) 2002-04-30 2007-03-11 Wyeth Corp Process for the preparation of 7-substituted-3- quinolinecarbonitriles
US20050010780A1 (en) * 2003-07-09 2005-01-13 Kane John Richard Method and apparatus for providing access to personal information
AU2004289243B2 (en) * 2003-11-06 2010-07-22 Wyeth Llc 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (CML)
AP2007004243A0 (en) 2005-04-25 2007-12-31 Pfizer Antibodies to myostatin
US20080300267A1 (en) 2005-05-16 2008-12-04 Barun Okram Compounds and Compositions as Protein Kinase Inhibitors
US20090163510A1 (en) 2005-07-15 2009-06-25 Bristol-Myers Squibb Company Methods of Identifying and Treating Individuals Exhibiting Mutant SRC Kinase Polypeptides
WO2007044411A2 (en) 2005-10-06 2007-04-19 Eli Lilly And Company Anti-myostatin antibodies
WO2007056177A2 (en) * 2005-11-04 2007-05-18 Bristol-Myers Squibb Pharma Company T315a and f317i mutations of bcr-abl kinase domain
CA2868899C (en) * 2007-06-01 2017-06-13 Wyeth Llc Treatment of imatinib resistant leukemia using 4-aminoquinoline-3-carbonitriles having mutation in the bcrabl gene

Also Published As

Publication number Publication date
DK2478905T3 (da) 2014-06-30
AU2008260070B2 (en) 2011-08-18
EP2478905A2 (en) 2012-07-25
EP3002009B1 (en) 2021-07-07
JP2010529038A (ja) 2010-08-26
EP2152267A2 (en) 2010-02-17
CA2964162A1 (en) 2008-12-11
CA2868899C (en) 2017-06-13
RU2009144128A (ru) 2011-07-20
PL3002009T3 (pl) 2021-12-13
AU2008260070A1 (en) 2008-12-11
HUE055524T2 (hu) 2021-11-29
EP3002009A2 (en) 2016-04-06
JP5888853B2 (ja) 2016-03-22
US11103497B2 (en) 2021-08-31
CY1124391T1 (el) 2022-07-22
CN101686973B (zh) 2013-06-19
CA2964162C (en) 2019-12-31
MX2009013069A (es) 2010-03-17
CL2008001577A1 (es) 2008-07-25
WO2008150957A2 (en) 2008-12-11
EP2478905B1 (en) 2014-05-14
CN101686973A (zh) 2010-03-31
IL202407A0 (en) 2010-06-30
EP2478905A3 (en) 2013-01-16
CA2688467C (en) 2015-05-12
KR101493543B1 (ko) 2015-02-13
EP2777704A3 (en) 2015-01-21
JP2014111629A (ja) 2014-06-19
HK1142812A1 (en) 2010-12-17
ZA200908480B (en) 2010-08-25
DK3002009T3 (da) 2021-08-02
ES2881391T3 (es) 2021-11-29
WO2008150957A3 (en) 2009-08-06
US20080318971A1 (en) 2008-12-25
TW200908982A (en) 2009-03-01
SI2478905T1 (sl) 2014-07-31
CA2868899A1 (en) 2008-12-11
PT2478905E (pt) 2014-07-16
EP3002009A3 (en) 2016-07-06
AU2008260070B9 (en) 2012-01-19
ES2477567T3 (es) 2014-07-17
RU2464026C2 (ru) 2012-10-20
CA2688467A1 (en) 2008-12-11
PL2478905T3 (pl) 2014-10-31
SI3002009T1 (sl) 2021-09-30
JP2016074700A (ja) 2016-05-12
BRPI0812355A2 (pt) 2015-01-27
PT3002009T (pt) 2021-08-02
EP2777704A2 (en) 2014-09-17
KR20100017983A (ko) 2010-02-16
PA8782301A1 (es) 2009-01-23

Similar Documents

Publication Publication Date Title
CY1115251T1 (el) Θεραπεια λευχαιμιας ανθεκτικης σε ιματινιμπη χρησιμοποιωντας 4-αμινοκινολινο-3-καρβονιτριλια
LTC2937350I2 (lt) 1'-pakeistieji karba-nukleozidų analogai, skirti antivirusiniam gydymui
EA201171367A1 (ru) Винилиндазолильные соединения
CY1121899T1 (el) Βοριουχα μικρομορια ως αντιφλεγμονωδεις παραγοντες
CY1112151T1 (el) Αγωνιστες τυπου πυριδονης του συζευγμενου με g-πρωτεϊνη υποδοχεα gpr119
EA200971068A1 (ru) Триазолиламинопиримидиновые соединения
CY1112595T1 (el) Αμιδοφαινοξυινδαζολια χρησιμα ως αναστολεις του c-met
CY1118523T1 (el) Πεπτιδικες ενωσεις για την θεραπεια του ανθεκτικου status epilepticus
CY2016026I2 (el) Μεθοδος για την θεραπεια του καρκινου με αντισταση στην γεφιτινιβη
MA32938B1 (fr) Composes organiques
CY1117752T1 (el) Τετρακυκλικη ενωση
EA201270619A1 (ru) Применение бетанехола для лечения ксеростомии
CY1110962T1 (el) Τρικυκλικες ενωσεις και η χρηση τους ως διαμορφωτες του υποδοχεα γλυκοκορτικοειδων
CR20110202A (es) Antagonistas de la via hedgehog de ftalazina disustituida
CY1113485T1 (el) Ενωσεις γεφυρωμενης-πιπεριδινης τυπου υποκατεστημενης-κινοξαλινης και οι χρησεις εξ' αυτων
DOP2010000302A (es) Antagonistas de la trayectoria hedgehog de ftalazina disustituida
CY1116802T1 (el) Ετεροκυκλικες ενωσεις
DK2173337T3 (da) Phosphaplatiner og deres anvendelse i behandlingen af cancer, der er resistent over for cisplatin og carboplatin
CY1115071T1 (el) Συνδυασμος ο οποιος περιεχει πακλιταξελη για τη θεραπευτικη αντιμετωπιση του καρκινου των ωοθηκων
CY1117674T1 (el) Χρηση παραγωγων των orvinol και thevinol ως θεραπευτικη αγωγη στην καταχρηση αλκοολ και φαρμακων
HUE038563T2 (hu) Rák kezelési eljárás
CL2008001837A1 (es) Uso de compuestos derivados de cinolin-3-carboxamida en el tratamiento de la esquizofrenia.
UA103468C2 (ru) Соединения циклоалкилокси- и гетероциклоалкилоксипиридина как модуляторы гистаминового рецептора н3
BRPI0816791A2 (pt) tratamento de sintomas vasomotores.
CY1112443T1 (el) Νεα θεραπευτικη χρηση για τη θεραπεια των λευχαιμιων